FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086202212> ?p ?o ?g. }

• W2086202212 endingPage "384" @default.
• W2086202212 startingPage "373" @default.
• W2086202212 abstract "Journal of Gastroenterology and HepatologyVolume 4, Issue 4 p. 373-384 Tumour markers of hepatocellular carcinoma MICHAEL C. KEW, Corresponding Author MICHAEL C. KEW Department of Medicine, University of the Witwatersrand Medical School, and Johannesburg and Baragwanath Hospitals, Johannesburg, South AfricaProf. M. C. Kew, Department of Medicine, Witwatersrand University Medical School, York Road, Parktown 2193, Johannesburg, South Africa.Search for more papers by this author MICHAEL C. KEW, Corresponding Author MICHAEL C. KEW Department of Medicine, University of the Witwatersrand Medical School, and Johannesburg and Baragwanath Hospitals, Johannesburg, South AfricaProf. M. C. Kew, Department of Medicine, Witwatersrand University Medical School, York Road, Parktown 2193, Johannesburg, South Africa.Search for more papers by this author First published: August 1989 https://doi.org/10.1111/j.1440-1746.1989.tb00848.xCitations: 21AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Shah D.V., Engelke J.A. & Suttie J.W. Abnormal prothrombin in the plasma of rats carrying hepatic tumour. Blood 1987; 69: 850– 4. 2 Kew M.C. & Dusheiko G.M. Paraneoplastic manifestations of hepatocellular carcinoma. In: P.D. Berk & T.C. Chalmers, eds, Frontiers in Liver Disease. Thieme-Stratton Inc., New York . 1981; 305– 19. 3 Bergstrand C.G. & Czar B. Paper electrophoretic study of human fetal serum proteins with demonstration of a new protein fraction. Scand. J. Clin. Lab. Invest. 1957; 9: 277– 86. 4 Abelev G.I. Alpha-fetoprotein in ontogenesis and its association with malignant tumour. Adv. Cancer Res. 1971; 14: 295– 358. 5 Tatarinov Y.S. Detection of embryo-specific alpha globulin in the blood sera of patients with liver tumour. Vopi. Med. Khim. 1964; 10: 90– 1. 6 Gitlin D. & Boesman M. Sites of serum alpha-fetoprotein synthesis in the human and in the rat. J. Clin. Invest. 1967; 46: 1010– 6. 7 Innis M.A. & Miller D.L. Alpha-fetoprotein gene expression. J. Biol. Chem. 1981; 255: 8994– 6. 8 Kew M.C. & Newberne P.M. Tumour markers in hepatocellular carcinoma. In: K. Okuda, I.R. MacKay eds , Hepatocellular Carcinoma. UICC, Geneva . 1982; 122– 35. 9 Ruoslahti E. & Seppala M. Studies on carcinofetal proteins: physical and chemical properties of human AFP. Int. J. Cancer 1971; 7: 218– 25. 10 Trichopoulos D., Sizaret P., Tabor E. et al. Alpha-fetoprotein levels of liver cancer patients and controls in a European population. Cancer 1980; 46: 736– 40. 11 Kew M.C. & Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in Blacks. Gastroenterology 1988; 94: 439– 42. 12 Kew M.C. Role of cirrhosis in hepatocarcinogenesis. In: P. Bannasch, D. Keppler, G. Weber, eds, Liver Cell Carcinoma. MTP Press, Lancaster . 1989 (in press). 13 Dibisceglie A.M., Dusheiko G.M., Paterson A.C. et al. Detection of alpha-fetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue. Brit. J. Cancer 1986; 54: 779– 85. 14 Aoyagi Y., Isemura M., Yosizawa Z. et al. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim. Biophys. Acta 1985; 830: 217– 23. 15 Baumah P.K., Harris R., James O.F.W. & Skillen A.W. Lentil-lectin-reactive alpha-fetoprotein in the differential diagnosis of benign and malignant liver disease. Clin. Chem. 1986; 32: 2083– 4. 16 Govindarajan S., Fong T-L. & Ashcavai M. Concanavalin A affinity of alpha-fetoprotein. Its use in differentiating tumours. Amer. J. Clin. Pathol. 1987; 88: 722– 4. 17 Aoyagi Y., Isemura M., Suzuki Y. et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 1985; 2: 1353– 4. 18 Baumah P.K., Cornell C., Cassels-Smith A.J. & Harris A.L. Fucosycation of alpha-fetoprotein in hepatocellular carcinomas. Lancet 1986; 1: 923– 4. 19 Kojima J., Kanatani M., Nakamura N., Kashiwagi T., Tohjoh F., & Akiyama N. Electrophoretic fractionation of serum gamma glutamyl transpeptidase in human hepatic cancer. Clin. Chim. Acta 1980; 106: 165– 72. 20 Kew M.C., Wolf P. & Rowe P. Tumour-associated isoenzymes of gamma glutamyl transferase in the serum of patients with hepatocellular carcinoma. Brit. J. Cancer 1984; 50 451– 5. 21 Smith A., Kay P.M., Johnson P.J. et al. Gamma glutamyl transpeptidase isoenzyme studies in primary hepatocellular carcinoma. Gut 1983; 24: A505. 22 Taniguchi H., House S., Kuzumaki N. et al. Monoclonal antibody against gamma glutamyl transferase from human primary hepatoma: its use in enzyme-linked immunosorbent assay of sera of cancer patients. J. Natl Cancer Inst. 1985; 75: 841– 7. 23 Liebman H.A., Furie B.C., Tong M.J. et al. Desgamma carboxy (abnormal) prothrombin as a serum marker of hepatocellular carcinoma. New Engl. J. Med. 1984; 310: 1427– 31. 24 Fujiyama S., Morishita T., Sagara K. et al. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Hepatogastroenterology 1986: 33: 201– 5. 25 Okuda H., Obata H., Nakanishi T. et al. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. J. Hepatol. 1987; 4: 357– 63. 26 Soulier J-P., Gozin D. & Lefreve J-J. A new method to assay des-gamma-carboxy prothrombin. Results obtained in 75 cases of hepatocellular carcinoma. Gastroenterology 1986; 91: 1258– 62. 27 King M.A., Kew M.C., Kuyl J.M. & Atkinson P.M. A comparison between des-gamma-carboxy prothrombin and alpha-fetoprotein as markers of hepatocellular carcinoma in Southern African Blacks. J. Gastroenterol. Hepatol. 1989; 4: 17– 24. 28 Robinson D. & Thorpe R. Human liver alpha-L-fucosidase. Clin. Chim. Acta 1973; 47: 403– 7. 29 Deugnier Y., Le Treut A., Glaise D. et al. A study of lysosomal enzyme activities in serum and leucocytes in chronic liver diseases. Clin. Chim. Acta 1980; 108: 385– 92. 30 Deugnier Y., David V., Brissot P. et al. Serum alpha-L-fucosidase. A new marker for the diagnosis of primary hepatic carcinoma. Hepatology 1984; 4: 889– 92. 31 Di Cioccio R.A., Barlow J.J. & Motta K.L. Evaluation of alpha-L-fucosidase as a marker of primary liver cancer. IRCS Med. Sci. 1985; 13: 849– 51. 32 Bukofzer S., Stass P.M., Kew M.C., De Beer M. & Groeneveld H.T. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma. Brit. J. Cancer 1989; 59: 417– 20. 33 Shively J.E. & Todd C.W. Carcino-embryonic antigen A: Chemistry and biology. In: S. Sell, ed., Cancer Markers: Diagnostic and Developmental Significance. Humana Press, New Jersey . 1980; 295– 314. 34 Macnab G.M., Urbanowicz J.M. & Kew M.C. Carcino-embryonic antigen in hepatocellular cancer. Brit. J. Cancer 1978: 38: 51– 4. 35 Melia W.M., Johnson P.J., Carter S., Munro-Neville A. & Williams R. Plasma carcino-embryonic antigen in the diagnosis and management of patients with hepatocellular carcinoma. Cancer 1981; 48: 1004– 8. 36 Richart C., Ruibal A., Monne J., Vilaseca J. & Guardia J. Carcino-embryonic antigen in liver disease. Lancet 1979; 1: 447– 8. 37 Moore T., Dhar P., Zamcheck H., Keeley A., Gottlieb L. & Kupchik H.Z. Carcino-embryonic antigens in liver disease. 1. Clinical and morphologic studies. Gastroenterology 1972; 63: 88– 94. 38 Kew M.C., Torrance J.D., Derman D. et al. Serum and tumour ferritins in primary liver cancer. Gut 1978; 19: 294– 9. 39 Alpert E., Coston R.L. & Drysdale J.W., Carcino-fetal human liver ferritins. Nature (London) 1973; 242: 194– 6. 40 Niitsu Y., Ohtsuka S., Kohgo Y., Watanabe N., Koseki J. & Urushizaki I. Hepatoma ferritin in the tissue and serum. Tumour Res. 1975; 10: 31– 41. 41 Whittaker D., Torrance J.D. & Kew M.C. Isolation of ferritin from human hepatocellular carcinoma. Scand. J. Haematol. 1984; 33: 432– 9. 42 Nagasue H., Yukaya H., Chang Y-C. & Ogawa Y. Serum ferritin after resection of hepatocellular carcinoma. Cancer 1986; 57: 1820– 3. 43 Powell L.W., Halliday J.W. & McKeering L.V. Studies of serum ferritin with emphasis on its importance in clinical medicine. In: R.R. Crighton, ed., Proteins of Iron Storage and Transport in Biochemistry and Medicine. Elsevier, Amsterdam . 1975; 215– 21. 44 Bjorklund B. On the nature and clinical use of tissue polypeptide antigen. Tumour Diagn. 1980; 1: 9– 20. 45 Kew M.C. & Berger E. The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma. Cancer 1986; 58: 127– 30. 46 Koprowski H., Herlyn M., Steplewski Z. & Sears H.F. Specific antigen in serum of patients with colon carcinoma. Science 1981; 2: 53– 5. 47 Atkinson B.F., Ernst C.C., Herlyn M., Steplewski Z., Sears H.F. & Koprowski H. Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res. 1982; 42: 4820– 3. 48 Kew M.C., Berger E.L. & Koprowski H., Carbohydrate antigen 19-9 as a serum marker of hepatocellular carcinoma: Comparison with alpha-fetoprotein. Brit. J. Cancer 1987; 56: 86– 8. 49 Conte N., Cecchettin M., Manente P., Valmachino G., Roiter I. & Pavan P. Calcitonin in hepatoma and cirrhosis. Acta Endocrinol. 1984; 106: 109– 11. 50 Dugard J., Kew M.C., Da Fonseca M. & Levin J. Serum immunoreactive calcitonin concentrations in hepatocellular carcinoma. South Afr. Med. J. 1982; 62: 271– 3. 51 Fujiyama S., Sagara K. & Sato T. Serum calcitonin levels in hepatocellular carcinoma and other liver diseases. Horm. Metabol. Res. 1986; 18: 421– 2. 52 Higashino K., Ohtani R., Kudo S. et al. Hepatocellular carcinoma and a variant alkaline phosphatase. Ann. Intern. Med. 1975: 83: 74– 8. 53 Kay P.M., Warnes T.W., Smith A. et al. Tumour markers of hepatocellular carcinoma–a different diagnostic approach is required in Caucasians and Chinese. Hepatology 1984; 4: 800. 54 Bukofzer S., Kew M.C. & Rowe P. The prevalence of variant alkaline phosphatase in hepatocellular carcinoma in southern African Blacks. Cancer 1988; 62: 978– 81. 55 Tsou K.C. & Lo K.W. Serum 5′-nucleotide phosphodiesterase isozyme-v test for human liver cancer. Cancer 1980; 45: 209– 13. 56 Lin K-M., Ye S-Y. & Lui Q-F. The significance of new abnormal isoenzymes of 5′-nucleotide phosphodiesterase in the diagnosis of human liver cancer. Int. J. Cancer 1988; 41: 30– 2. 57 Waxman S. & Gilbert H.S. A tumor-related Vitamin B12 binding protein in adolescent hepatoma. New Engl. J. Med. 1973; 282: 1053– 6. 58 Paradinas F.J., Melia W.M., Wilkinson M.L. et al. High serum Vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Brit. Med. J. 1982; 285: 840– 2. 59 Van Tonder S., Kew M.C., Hodkinson J., Metz J. & Fernandes-Costa F. Serum Vitamin B12 binders in South African Blacks with hepatocellular carcinoma. Cancer 1985; 56: 789– 92. 60 Collier N.A., Weinbren K., Bloom S.R. et al. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet 1984; 1: 538– 40. 61 Tang Z.Y. Subclinical Hepatocellular Carcinoma. China Academic Publishers, Shanghai . 1985. 62 Chen D.S., Shen J.C., Sing J.L. et al. Small hepatocellular carcinoma–a clinico-pathologic study in 13 patients. Gastroenterology 1982; 83: 1109– 19. 63 Okuda K., Kotoda K., Obata H. et al. Clinical observations during a relatively early stage of hepatocellular carcinoma with special reference to serum alpha-fetoprotein levels. Gastroenterology 1975; 69: 226– 34. 64 Shinagawa T., Ohto M., Kumura K. et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on this utility of real-time ultrasonography. Gastroenterology 1984; 86: 495– 502. 65 Mori Y., Iwama S., Mori T., et al. Liver-specific F antigen in the serum of patients with liver diseases and the detection of early stage hepatocellular carcinoma. Clin. Chim. Acta 1987; 164: 127– 37. Citing Literature Volume4, Issue4August 1989Pages 373-384 ReferencesRelatedInformation" @default.
• W2086202212 created "2016-06-24" @default.
• W2086202212 creator A5081985439 @default.
• W2086202212 date "1989-08-01" @default.
• W2086202212 modified "2023-09-27" @default.
• W2086202212 title "Tumour markers of hepatocellular carcinoma" @default.
• W2086202212 cites W1559589970 @default.
• W2086202212 cites W1575988806 @default.
• W2086202212 cites W172136927 @default.
• W2086202212 cites W1760852900 @default.
• W2086202212 cites W1843743847 @default.
• W2086202212 cites W1867279571 @default.
• W2086202212 cites W1929094539 @default.
• W2086202212 cites W1944584437 @default.
• W2086202212 cites W1965674935 @default.
• W2086202212 cites W1969787982 @default.
• W2086202212 cites W1970053887 @default.
• W2086202212 cites W1971384542 @default.
• W2086202212 cites W1972594734 @default.
• W2086202212 cites W1979497940 @default.
• W2086202212 cites W2001558763 @default.
• W2086202212 cites W2001954483 @default.
• W2086202212 cites W2003581787 @default.
• W2086202212 cites W2005632274 @default.
• W2086202212 cites W2007861184 @default.
• W2086202212 cites W2012871544 @default.
• W2086202212 cites W2020115474 @default.
• W2086202212 cites W2027986463 @default.
• W2086202212 cites W2034571278 @default.
• W2086202212 cites W2038181352 @default.
• W2086202212 cites W2040875689 @default.
• W2086202212 cites W2042541474 @default.
• W2086202212 cites W2050730431 @default.
• W2086202212 cites W2051377899 @default.
• W2086202212 cites W2051426051 @default.
• W2086202212 cites W2056774453 @default.
• W2086202212 cites W2061076961 @default.
• W2086202212 cites W2061968192 @default.
• W2086202212 cites W2062569097 @default.
• W2086202212 cites W2065335678 @default.
• W2086202212 cites W2066081469 @default.
• W2086202212 cites W2071873413 @default.
• W2086202212 cites W2077729203 @default.
• W2086202212 cites W2078769264 @default.
• W2086202212 cites W2079367656 @default.
• W2086202212 cites W2082672980 @default.
• W2086202212 cites W2089731709 @default.
• W2086202212 cites W2098001605 @default.
• W2086202212 cites W2126921243 @default.
• W2086202212 cites W2326054973 @default.
• W2086202212 cites W2330134488 @default.
• W2086202212 cites W2339039657 @default.
• W2086202212 cites W2395081004 @default.
• W2086202212 cites W36943512 @default.
• W2086202212 cites W4297633268 @default.
• W2086202212 cites W4317563520 @default.
• W2086202212 doi "https://doi.org/10.1111/j.1440-1746.1989.tb00848.x" @default.
• W2086202212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2562350" @default.
• W2086202212 hasPublicationYear "1989" @default.
• W2086202212 type Work @default.
• W2086202212 sameAs 2086202212 @default.
• W2086202212 citedByCount "25" @default.
• W2086202212 countsByYear W20862022122012 @default.
• W2086202212 countsByYear W20862022122013 @default.
• W2086202212 countsByYear W20862022122014 @default.
• W2086202212 countsByYear W20862022122015 @default.
• W2086202212 countsByYear W20862022122016 @default.
• W2086202212 countsByYear W20862022122017 @default.
• W2086202212 crossrefType "journal-article" @default.
• W2086202212 hasAuthorship W2086202212A5081985439 @default.
• W2086202212 hasConcept C126322002 @default.
• W2086202212 hasConcept C142724271 @default.
• W2086202212 hasConcept C143998085 @default.
• W2086202212 hasConcept C2777546739 @default.
• W2086202212 hasConcept C2778019345 @default.
• W2086202212 hasConcept C61434518 @default.
• W2086202212 hasConcept C71924100 @default.
• W2086202212 hasConceptScore W2086202212C126322002 @default.
• W2086202212 hasConceptScore W2086202212C142724271 @default.
• W2086202212 hasConceptScore W2086202212C143998085 @default.
• W2086202212 hasConceptScore W2086202212C2777546739 @default.
• W2086202212 hasConceptScore W2086202212C2778019345 @default.
• W2086202212 hasConceptScore W2086202212C61434518 @default.
• W2086202212 hasConceptScore W2086202212C71924100 @default.
• W2086202212 hasIssue "4" @default.
• W2086202212 hasLocation W20862022121 @default.
• W2086202212 hasLocation W20862022122 @default.
• W2086202212 hasOpenAccess W2086202212 @default.
• W2086202212 hasPrimaryLocation W20862022121 @default.
• W2086202212 hasRelatedWork W2014435840 @default.
• W2086202212 hasRelatedWork W2019250753 @default.
• W2086202212 hasRelatedWork W2102644969 @default.
• W2086202212 hasRelatedWork W2165306189 @default.
• W2086202212 hasRelatedWork W2434614770 @default.
• W2086202212 hasRelatedWork W2766588635 @default.
• W2086202212 hasRelatedWork W2967287585 @default.
• W2086202212 hasRelatedWork W3208701539 @default.
• W2086202212 hasRelatedWork W4313346385 @default.

• next